Biosimilars Industry Trends

Near or Far

So near but yet so far — could well describe the situation molecule-tweaking drug makers of India find themselves in. For years, they have been in the front and centre of the generics revolution — which is essentially about selling off-patent versions of expensive medicines invented by multinationals. While they remain good at the chemistry of molecular tweaking of patented drugs, they seem to have run into a high technology wall when trying to do the same with biologic medicines.

Biosimilars — as off-patent biologics are called — are turning out to be a very closed opportunity for pharma firms that boast of a biotech products portfolio.

Industry estimates that by 2014, biologics worth $60 billion will go off patent in the US and Europe.That, experts say, is a massive opportunity for local companies such as Cipla, Biocon, Dr Reddy’s Laboratories and Lupin, which are in the process of developing biosimilars.

Source

Recently posted interesting insights on the Veeda CR Corporate blog on are posted in the section titled Central Nervous System in blog titled: Generics "Glitter" or "Glittering" Generics